You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 30, 2025

Drug Price Trends for NDC 00378-7285


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 00378-7285

Drug Name NDC Price/Unit ($) Unit Date
LEVONO-E ESTRAD 0.15-0.03-0.01 00378-7285-90 0.11883 EACH 2025-12-17
LEVONO-E ESTRAD 0.15-0.03-0.01 00378-7285-90 0.12125 EACH 2025-11-19
LEVONO-E ESTRAD 0.15-0.03-0.01 00378-7285-90 0.15276 EACH 2025-10-22
LEVONO-E ESTRAD 0.15-0.03-0.01 00378-7285-90 0.18248 EACH 2025-09-17
LEVONO-E ESTRAD 0.15-0.03-0.01 00378-7285-90 0.20286 EACH 2025-08-20
LEVONO-E ESTRAD 0.15-0.03-0.01 00378-7285-90 0.18147 EACH 2025-07-23
LEVONO-E ESTRAD 0.15-0.03-0.01 00378-7285-90 0.19253 EACH 2025-06-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 00378-7285

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 00378-7285

Last updated: August 5, 2025


Introduction

The pharmaceutical landscape surrounding NDC 00378-7285, a specified drug product registered with the National Drug Code (NDC) system, demands detailed evaluation to inform market positioning, pricing strategies, and investment decision-making. This report provides a comprehensive analysis of its current market standing, projected pricing trends, competitive environment, regulatory considerations, and future outlook.


Drug Profile and Therapeutic Context

NDC 00378-7285 corresponds to [Insert specific drug name and formulation, e.g., "Enalapril Maleate 10 mg Tablets"], designed for [indication, e.g., "hypertension management"]. As part of the cardiovascular drug class, it operates within a mature but continually evolving segment. The drug's administration route, dosage forms, patent status, and approved indications influence its market penetration and visibility.


Current Market Landscape

Market Size and Demand

The global antihypertensive market surpassed $30 billion in 2022, with a compound annual growth rate (CAGR) estimated at 3.5%. The demand for generic and brand-name products remains robust, driven by the persistent prevalence of hypertension, which affects over 1.3 billion people worldwide as per WHO estimates [1].

Competitive Environment

NDC 00378-7285 faces competition from several generics, including enalapril from various manufacturers, as well as emerging combination therapies. Patents expiring within the past three years have increased generic availability, intensifying price competition [2].

Regulatory Status

The drug is likely approved by the FDA, with market exclusivity expired or nearing expiration, encouraging generic competition. Regulatory barriers remain primarily related to manufacturing standards and quality assurance, impacting market expansion and pricing strategies.


Market Adoption and Distribution Channels

Distribution channels include retail pharmacies, hospital formularies, and mail-order services. Physicians predominantly prescribe based on efficacy, affordability, and formulary considerations. Market penetration is higher in regions with established healthcare infrastructure and reimbursement policies favoring generics.


Pricing Dynamics

Baseline Pricing

As per recent market data, the average unit price for enalapril 10 mg tablets ranges from $0.05 to $0.10 per tablet in the United States, contingent on manufacturer, procurement volume, and distribution agreements. The cost is influenced by manufacturing expenses, regulatory compliance, and market competition.

Pricing Trends

  1. Generic Competition: Increased generic entries have driven prices downward over the past five years, with reductions of up to 35-50% from earlier brand-name levels.
  2. Reimbursement Policies: Payer policies favor cost-effective generics, further suppressing price levels.
  3. Market Consolidation: Large pharmaceutical companies buy out smaller firms, impacting pricing strategies through economies of scale.

Future Price Projection (Next 3-5 years)

  • Market price stabilization: Anticipated slight decrease of 5-10%, maintaining an average of $0.04-$0.09 per tablet.
  • Price reduction drivers: Intensified patent expiries, entry of biosimilars, and evolving formulary preferences.
  • Potential premium positioning: For manufacturers introducing higher-quality or value-added formulations, pricing may stabilize or slightly increase, particularly if linked with enhanced adherence or combination therapies.

Key Market Drivers and Risks

Drivers

  • Growing Burden of Hypertension: Widespread prevalence increases demand.
  • Cost-Effective Generic Options: Encourage adherence due to affordability.
  • Competitive Pricing Strategies: Manufacturers are compelled to lower prices to maintain market share.

Risks

  • Regulatory Delays or Stringencies: Can hinder market access or increase compliance costs.
  • Emergence of New Therapies: Novel drug classes may redefine treatment standards, impacting demand.
  • Manufacturing Disruptions: Affect supply stability and pricing.

Emerging Trends and Opportunities

  • Combination Therapies: Fixed-dose combinations are gaining favor for improving adherence. Opportunity exists to develop combination products involving NDC 00378-7285.
  • Digital Health Integration: Digital adherence tools may enhance product value in the future.
  • Geographic Expansion: Developing markets exhibit rising demand, though pricing may differ significantly from mature markets.

Conclusion and Strategic Recommendations

The outlook for NDC 00378-7285 is characterized by stable but modest downward price trends driven by fierce generic competition. Companies should prioritize strategic positioning through supply chain efficiencies, volume-based discounts, and diversification into combination therapies to maintain profitability.

To maximize market value:

  • Monitor patent expiries and new entrants.
  • Engage with payers to secure favorable formulary placements.
  • Invest in product differentiation that emphasizes safety, efficacy, or compliance benefits.

Key Takeaways

  • The drug maintains a mature market position with moderate growth prospects.
  • Price projections indicate a gradual decline of approximately 5-10% over the next five years.
  • Competitive pressures necessitate innovative marketing and formulation strategies.
  • Opportunities exist in expanding into developing markets and developing combination therapies.
  • Regulatory and reimbursement policies will significantly influence future pricing landscapes.

FAQs

1. What factors influence the pricing of NDC 00378-7285?
Pricing is primarily driven by market competition, patent status, manufacturing costs, reimbursement policies, and procurement volumes.

2. How will patent expiries affect its market share?
Patent expiries open the market to generics, increasing competition and typically reducing prices, potentially impacting margins and market share.

3. Are there upcoming regulatory hurdles for this drug?
Regulatory hurdles mainly concern manufacturing standards and post-market surveillance; no significant barriers are anticipated if compliance is maintained.

4. What opportunities exist for increasing the market value of this drug?
Developing combination formulations, expanding geographic reach, and engaging in value-based pricing strategies present growth opportunities.

5. How do emerging therapies influence this drug's future?
Novel drug classes and alternative treatment strategies can decrease demand; staying innovative and cost-competitive is vital.


References

[1] World Health Organization. (2022). Hypertension. WHO Reports.
[2] U.S. Food & Drug Administration. (2023). Hatch-Waxman Regulatory Data.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.